Monday, 31 August 2026European Markets

NACON Stock Is 27% Down In The Last 21 Sessions

Loading stream...

(vianews) - shares of nacon (cac 40: nacon.pa) dropped by a staggering 27.53% in 21 sessions from €2.81 to €2.04 at 17:06 est on friday, after three consecutive sessions in a row of losses. cac 40 is jumping 1.44% to €7,396.06, following the last session's downward trend.

nacon's last close was €2.08, 65.98% below its 52-week high of €6.10.

about nacon

nacon s.a. designs and distributes games and gaming accessories in france and internationally. the company offers accessories, including headsets, microphones, controllers, rig, racing wheels, gaming chairs, keyboards, mice, audio, and console accessories. it also develops and publishes video games in various categories, such as action-adventure, racing, sport, and simulation. the company was incorporated in 2019 and is based in fretin, france. nacon s.a. is a subsidiary of bigben interactive sa.

earnings per share

as for profitability, nacon has a trailing twelve months eps of €0.18.

pe ratio

nacon has a trailing twelve months price to earnings ratio of 11.33. meaning, the purchaser of the share is investing €11.33 for every euro of annual earnings.

volume

today's last reported volume for nacon is 55585 which is 54.29% below its average volume of 70773.

more news about nacon (nacon.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com